M&A / Deals Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities BioSpaceGilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company's usual M A pace.M&A / DealsRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) BioSpace Gilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company’s usual M A pace. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment UpdateNext: With 3 quick buyouts, Gilead leans into its latest transformation Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
